Cover Image
市場調查報告書

糖尿病、減肥藥的全球市場:胰島素及GPCR維持商業性的重要性,另一方面減重治療仍殘留高未滿足需求

Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment

出版商 GBI Research 商品編碼 367993
出版日期 內容資訊 英文 100 Pages
訂單完成後即時交付
價格
Back to Top
糖尿病、減肥藥的全球市場:胰島素及GPCR維持商業性的重要性,另一方面減重治療仍殘留高未滿足需求 Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment
出版日期: 2016年08月01日 內容資訊: 英文 100 Pages
簡介

本報告提供糖尿病、減肥藥市場相關調查分析,主要上市產品,開發平台情形的評估,市場預測,企業分析,策略性整合等系統性資訊。

第1章 目錄

第2章 簡介

  • 治療領域的簡介
    • 糖尿病
    • 肥胖
  • 症狀
    • 糖尿病
    • 肥胖
  • 流行病學、病理學
    • 第一型糖尿病
    • 第二型糖尿病
    • 肥胖
    • 肥胖與T2DM (第二型糖尿病)的關連
  • 合併症、併發症
  • 流行病學模式、預測
    • 糖尿病
    • 肥胖
  • 治療
    • 糖尿病的藥物療法
    • 胰島素治療
    • 胰澱粉多胜肽類似物
    • 肥胖的藥物療法

第3章 上市產品

  • 概要
  • 糖尿病:前8名主要上市產品
    • Lantus (insulin glargine) - Sanofi
    • Novolog (insulin aspart) - Novo Nordisk
    • Januvia (sitagliptin phosphate) - Merck & Co
    • Levemir (insulin detemir) - Novo Nordisk
    • Victoza (liraglutide) - Novo Nordisk
    • Humalog (insulin lispro) - Eli Lilly
    • Janumet (metformin hydrochloride plus sitagliptin phosphate) - Merck & Co
    • 新市場參與企業
  • 糖尿病概要
    • Saxenda (liraglutide)
    • Belviq (lorcaserin hydrochloride)
    • Xenical (orlistat)
    • Contrave (bupropion hydrochloride plus naltrexone)
  • 結論

第4章 開發平台形勢的變化

  • 概要
  • 開發平台開發形勢
  • 開發平台的分子標的
  • 臨床實驗
    • 失敗率:各開發階段、症狀、分子類型、分子標的
    • 臨床實驗期間:各開發階段、症狀、分子類型、分子標的
    • 臨床實驗規模:各開發階段、症狀、分子類型、分子標的
    • 臨床實驗計劃規模的總合:各開發階段、症狀、分子類型、分子標的
  • 開發平台的後期階段產品醫藥品
    • Saxagliptin plus dapagliflozin (dapagliflozin propanediol plus saxagliptin) - AstraZeneca
    • Semaglutide (OG-217SC and NN-9535 - Oral and Subcutaneous) - Novo Nordisk
    • LixiLan (insulin glargine plus lixisenatide) - Sanofi
    • NN-1218 (insulin aspart) - Novo Nordisk
    • Ertugliflozin (PF-04971729) - Merck & Co/Pfizer
    • Sotagliflozin - Lexicon Pharmaceuticals
  • 結論

第5章 多方案的市場預測

  • 整體市場規模
  • 學名藥的普及
  • 收益預測:各分子標的
    • 胰島素受體
    • GLP1R
    • DPP4
    • SGLT2
    • AMPK
    • ABCC8
  • 結論

第6章 企業分析、定位

  • 收益、市場佔有率分析:各企業
    • Novo Nordisk
    • Eli Lilly
    • Sanofi
    • Merck & Co
    • AstraZeneca
    • 武田藥品工業
  • 企業形勢
  • 上市、開發平台的組合分析

第7章 策略性整合

  • 許可證交易
  • 共同開發交易

第8章 附錄

圖表

目錄
Product Code: GBIHC413MR

Executive Summary

Diabetes is a chronic metabolic disease characterized by hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia in diabetic patients is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). Obesity, meanwhile, is defined as abnormal or excessive body fat accumulation that presents a risk to health.

A current global rise in T2DM prevalence is intrinsically linked with the current global rise in obesity. The rapidly increasing global obesity prevalence has resulted in it being considered a global epidemic, and there is a vast and growing global patient population potentially requiring pharmacotherapeutic treatment.

Historically anti-obesity therapeutics have been out of favor due to safety concerns. Both diabetes and obesity products are commonly associated with cardiovascular adverse events, and this is further compounded by concerns relating to cancer development through long-term usage of anti-obesity products. This has resulted in an unmet need for products with favorable safety and efficacy profiles, particularly in the case of obesity.

The market size for the diabetes and obesity disease cluster is set to increase considerably, driven by the success of a number of T2DM pipeline products, and a rapidly expanding global patient population. However, obesity pipeline activity is set to remain markedly low, despite a patient population of epidemic proportions.

Scope

  • What are the current treatment options for diabetes and obesity?
  • What are the common molecular targets of pipeline therapies, and how strongly do they overlap with the current market?
  • Will the pipeline address unmet needs such as a lack of safe treatment options for diabetes and obesity patients?
  • Which late-stage pipeline products are likely to impact the current market?
  • How are revenues of key companies, targets and molecule types anticipated to change over the forecast period?
  • Which companies are anticipated to be the most prominent players over the next seven years?
  • How do licensing and co-development deals compare between diabetes and obesity?

Reasons to buy

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the diabetes and obesity market in terms of the clinical and commercial standing of current dominant therapies. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
  • Analyze the diabetes and obesity pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There is a strong contrast in the amount of pipeline activity for diabetes and obesity.
  • Analyze how individual company, molecule type and molecular target revenues are anticipated to change over the forecast period, highlighting prominent companies and the most promising molecule types and targets.
  • Identify which companies are the current key players for the disease cluster, and how this pattern is anticipated to change over the forecast period.
  • Identify commercial opportunities in the diabetes and obesity deals landscape by analyzing trends in licensing and co-development deals by stage of development, molecule type and molecular target.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
    • 2.1.1. Diabetes
    • 2.1.2. Obesity
  • 2.2. Symptoms
    • 2.2.1. Diabetes
    • 2.2.2. Obesity
  • 2.3. Etiology and Pathophysiology
    • 2.3.1. Type 1 Diabetes Mellitus
    • 2.3.2. Type 2 Diabetes Mellitus
    • 2.3.3. Obesity
    • 2.3.4. The Association between Obesity and T2DM
  • 2.4. Comorbidities and Complications
  • 2.5. Epidemiology Patterns and Forecasts across the 7MM
    • 2.5.1. Diabetes
    • 2.5.2. Obesity
  • 2.6. Treatment
    • 2.6.1. Diabetic Pharmacotherapeutics
    • 2.6.2. Insulin Therapy
    • 2.6.3. Amylin Analogs
    • 2.6.4. Obesity Pharmacotherapeutics

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. Diabetes - Top Eight Key Marketed Products
    • 3.2.1. Lantus (insulin glargine) - Sanofi
    • 3.2.2. Novolog (insulin aspart) - Novo Nordisk
    • 3.2.3. Januvia (sitagliptin phosphate) - Merck & Co
    • 3.2.4. Levemir (insulin detemir) - Novo Nordisk
    • 3.2.5. Victoza (liraglutide) - Novo Nordisk
    • 3.2.6. Humalog (insulin lispro) - Eli Lilly
    • 3.2.7. Janumet (metformin hydrochloride plus sitagliptin phosphate) - Merck & Co
    • 3.2.8. New Market Entrants
  • 3.3. Obesity Overview
    • 3.3.1. Saxenda (liraglutide)
    • 3.3.2. Belviq (lorcaserin hydrochloride)
    • 3.3.3. Xenical (orlistat)
    • 3.3.4. Contrave (bupropion hydrochloride plus naltrexone)
  • 3.4. Conclusion

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Pipeline Development Landscape
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.2. Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.3. Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.4. Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
  • 4.5. Late-Stage Drugs of the Developmental Pipeline
    • 4.5.1. Saxagliptin plus dapagliflozin (dapagliflozin propanediol plus saxagliptin) - AstraZeneca
    • 4.5.2. Semaglutide (OG-217SC and NN-9535 - Oral and Subcutaneous) - Novo Nordisk
    • 4.5.3. LixiLan (insulin glargine plus lixisenatide) - Sanofi
    • 4.5.4. NN-1218 (insulin aspart) - Novo Nordisk
    • 4.5.5. Ertugliflozin (PF-04971729) - Merck & Co/Pfizer
    • 4.5.6. Sotagliflozin - Lexicon Pharmaceuticals
  • 4.6. Conclusion

5. Multi Scenario Market Forecast to 2022

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
  • 5.3. Revenue Forecast by Molecular Target
    • 5.3.1. Insulin Receptor
    • 5.3.2. GLP1R
    • 5.3.3. DPP4
    • 5.3.4. SGLT2
    • 5.3.5. AMPK
    • 5.3.6. ABCC8
  • 5.4. Conclusion

6. Company Analysis and Positioning

  • 6.1. Revenue and Market Share Analysis by Company
    • 6.1.1. Novo Nordisk
    • 6.1.2. Eli Lilly
    • 6.1.3. Sanofi
    • 6.1.4. Merck & Co
    • 6.1.5. AstraZeneca
    • 6.1.6. Takeda
  • 6.2. Company Landscape
  • 6.3. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deals by Region, Year and Value
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type, Mechanism of Action and Value
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Year and Value
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type, Mechanism of Action and Value

8. Appendix

  • 8.1. References
  • 8.2. Abbreviations
  • 8.3. Methodology
    • 8.3.1. Coverage
    • 8.3.2. Secondary Research
    • 8.3.3. Market Size and Revenue Forecasts
    • 8.3.4. Pipeline Analysis
    • 8.3.5. Competitive Landscape
  • 8.4. Contact Us
  • 8.5. Disclaimer

List of Tables

  • Table 1: Body Mass Index Classifications
  • Table 2: Epidemiology of T1DM, T2DM and Obesity, Global, 2016
  • Table 3: Obesity Therapeutics Market, Seven Major Markets, Summary of the Action, Efficacy and Pathway of the Six Top-Selling FDA-Approved Pharmacotherapeutics, 2015
  • Table 4: Diabetes and Obesity Therapeutics Market, Global, Number of Pipeline Products, 2015

List of Figures

  • Figure 1: Diabetes and Obesity Therapeutics Market, Seven Major Markets, Prevalence (%) and Number of Patients ('000) with T1DM, 2015-2022
  • Figure 2: Diabetes and Obesity Therapeutics Market, Seven Major Markets, Prevalence (%) and Number of Patients ('000) with T2DM, 2015-2022
  • Figure 3: Diabetes and Obesity Therapeutics Market, Seven Major Markets, Prevalence (%) and Number of Patients ('000) with Obesity, 2015-2022
  • Figure 4: Diabetes and Obesity Therapeutics Market, Seven Major Markets, Key Marketed Products and Indications, 2015
  • Figure 5 : Diabetes Therapeutics Market, Global, Annual Revenue for Lantus ($bn), 2006-2022
  • Figure 6 : Diabetes Therapeutics Market, Global, Annual Revenue for Novolog ($bn), 2006-2022
  • Figure 7 : Diabetes Therapeutics Market, Global, Annual Revenue for Januvia ($bn), 2006-2022
  • Figure 8: Diabetes Therapeutics Market, Global, Annual Revenue for Levemir ($bn), 2006-2022
  • Figure 9: Diabetes Therapeutics Market, Global, Annual Revenue for Victoza ($bn), 2006-2022
  • Figure 10: Diabetes Therapeutics Market, Global, Annual Revenue for Humalog ($bn), 2006-2022
  • Figure 11: Diabetes Therapeutics Market, Global, Annual Revenue for Janumet ($bn), 2006-2022
  • Figure 12: Diabetes Therapeutics Market, Global, Current and Pipeline indications of Additional Therapeutics for which Annual Revenue is Expected to Exceed $2 billion by 2022
  • Figure 13: Diabetes Therapeutics Market, Global, Expected Revenues for Additional Therapeutics for which Annual Revenue is Expected to Exceed $2 billion by 2022
  • Figure 14: Obesity Therapeutics Market, Global, Annual Revenue for Saxenda ($m), 2015-2022
  • Figure 15: Obesity Therapeutics Market, Global, Annual Revenue for Belviq ($m), 2013-2022
  • Figure 16: Obesity Therapeutics Market, Global, Annual Revenue for Xenical ($m), 2006-2012
  • Figure 17: Overall Pharmaceutical Industry Pipeline by Therapy Area, Global, 2015
  • Figure 18: Diabetes and Obesity Therapeutics Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2016
  • Figure 19: Diabetes and Obesity Therapeutics Market, Global, Pipeline by Indication and Stage of Development, 2016
  • Figure 20: Diabetes and Obesity Therapeutics Market, Global, Pipeline by Indication and Molecule Type, 2016
  • Figure 21: Diabetes and Obesity Therapeutics Market, Global, Pipeline for by Molecular Target, 2016
  • Figure 22: Diabetes and Obesity Therapeutics Market, Global, Pipeline by Indication and Molecular Target, 2016
  • Figure 23: Diabetes and Obesity Therapeutics Market, Global, Pipeline by Indication and 'Multiple' Subcategory of Molecular Target, 2016
  • Figure 24: Diabetes and Obesity Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development, 2006-2016
  • Figure 25: Diabetes and Obesity Therapeutics Market, Global, Clinical Trial Attrition Rates by Indication and Stage of Development, 2006-2015
  • Figure 26: Diabetes and Obesity Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type, 2006-2016
  • Figure 27: Diabetes and Obesity Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target, 2006-2016
  • Figure 28: Diabetes and Obesity Therapeutics Market, Global, Clinical Trial Duration (months) by Stage of Development and Indication, 2006-2016
  • Figure 29: Diabetes and Obesity Therapeutics Market, Global, Clinical Trial Duration (months) by Stage of Development and Molecule Type, 2006-2015
  • Figure 30: Diabetes and Obesity Therapeutics Market, Global, Clinical Trial Duration (months) by Stage of Development and Molecular Target, 2006-2016
  • Figure 31: Diabetes and Obesity Therapeutics Market, Global, Clinical Trial Size (participants) by Stage of Development and Indication, 2006-2015
  • Figure 32: Diabetes and Obesity Therapeutics Market, Global, Clinical Trial Size (participants) by Stage of Development and Molecule Type, 2006-2015
  • Figure 33: Diabetes and Obesity Therapeutics Market, Global, Clinical Trial Size (participants) by Stage of Development and Molecular Target, 2006-2015
  • Figure 34: Diabetes and Obesity Therapeutics Market, Global, Clinical Program Size (participants) by Stage of Development and Indication, 2006-2015
  • Figure 35: Diabetes and Obesity Therapeutics Market, Global, Clinical Program Size (participants) by Stage of Development and Molecule Type, 2006-2015
  • Figure 36: Diabetes and Obesity Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target, 2006-2015
  • Figure 37: Diabetes and Obesity Therapeutics Market, Global, Revenue Forecast for Saxagliptin plus Dapagliflozin ($m), 2015-2022
  • Figure 38: Diabetes and Obesity Therapeutics Market, Global, Revenue Forecast for NN-9535 ($m), 2015-2022
  • Figure 39: Diabetes and Obesity Therapeutics Market, Global, Revenue Forecast for LixiLan ($m), 2015-2022
  • Figure 40: Diabetes and Obesity Therapeutics Market, Global, Revenue Forecast for NN-1218 ($m), 2015-2022
  • Figure 41: Diabetes and Obesity Therapeutics Market, Global, Revenue Forecast for Ertugliflozin ($m), 2015-2022
  • Figure 42: Diabetes and Obesity Therapeutics Market, Global, Revenue Forecast for Sotagliflozin ($m), 2015-2022
  • Figure 43: Diabetes and Obesity Therapeutics Market, Global, Market Size ($bn), 2015-2022
  • Figure 44: Diabetes and Obesity Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($bn), 2015-2022
  • Figure 45: Diabetes and Obesity Therapeutics Market, Global, Annual Revenue Forecast for Insulin Mimetics ($bn), 2015-2022
  • Figure 46: Diabetes and Obesity Therapeutics Market, Global, Annual Revenue Forecast for GLP1R Agonists ($bn), 2015-2022
  • Figure 47: Diabetes and Obesity Therapeutics Market , Global, Annual Revenue Forecast for DPP4 Inhibitors ($bn), 2015-2022
  • Figure 48: Diabetes and Obesity Therapeutics Market , Global, Annual Revenue Forecast for SGLT2 Inhibitors ($bn), 2015-2022
  • Figure 49: Diabetes and Obesity Therapeutics Market, Global, Annual Revenue Forecast for AMPK Activators ($bn), 2015-2022
  • Figure 50: Diabetes and Obesity Therapeutics Market, Global, Annual Revenue Forecast for ABCC8 Inhibitors ($m), 2015-2022
  • Figure 51: Diabetes and Obesity Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022
  • Figure 52: Diabetes and Obesity Therapeutics Market, Global, Forecast Revenues by Company ($m), 2015-2022
  • Figure 53: Diabetes and Obesity Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022
  • Figure 54: Diabetes and Obesity Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2015-2022
  • Figure 55: Diabetes and Obesity Therapeutics Market , Global, Revenues by Product Type ($bn), 2015-2022
  • Figure 56: Diabetes and Obesity Therapeutics Market, Global, Annual Revenue Forecast for Novo Nordisk ($bn), 2015-2022
  • Figure 57: Diabetes and Obesity Therapeutics Market, Global, Annual Revenue Forecast for Eli Lilly ($bn), 2015-2022
  • Figure 58: Diabetes and Obesity Therapeutics Market, Global, Annual Revenue Forecast for Sanofi ($bn), 2015-2022
  • Figure 59: Diabetes and Obesity Therapeutics Market, Global, Annual Revenue Forecast for Merck & Co ($bn), 2015-2022
  • Figure 60: Diabetes and Obesity Therapeutics Market, Global, Annual Revenue Forecast for AstraZeneca ($bn), 2015-2022
  • Figure 61: Diabetes and Obesity Therapeutics Market, Global, Annual Revenue Forecast for Takeda Pharmaceutical Company Limited ($bn), 2015-2022
  • Figure 62: Diabetes and Obesity Therapeutics Market , Global, High-activity and Late-stage Companies by Type, 2015
  • Figure 63: Diabetes and Obesity Therapeutics Market, Global, Companies by Specialization and Type, 2015
  • Figure 64: Diabetes and Obesity Therapeutics Market, Global, Proportion of Total Company Revenue Attributable to Disease Cluster, 2015-2022
  • Figure 65: Diabetes and Obesity Therapeutics Market , Global, Licensing Deals by Region, Value And Year, 2006-2015
  • Figure 66: Diabetes and Obesity Therapeutics Market, Global, Number of Licensing Deals by Value and Stage of Development, 2006-2015
  • Figure 67: Diabetes and Obesity Therapeutics Market , Global, Number of Licensing Deals by Molecule Type and Molecular Target, 2006-2015
  • Figure 68: Diabetes and Obesity Therapeutics Market , Global, Co-development Deals by Region, Value and Year, 2006-2015
  • Figure 69: Diabetes and Obesity Therapeutics Market, Global, Co-development Deals by Value and Stage of Development, 2006-2015
  • Figure 70: Diabetes and Obesity Therapeutics Market , Global, Number of Co-development Deals by Molecule Type and Molecular Target, 2006-2015
Back to Top